Molina: Rate increases may only offset medical costs; JPMorgan maintains underweight bond recommendation

Third-quarter results met expectations, so why is a profit recovery not yet assured?

Premium revenue and medical care ratios (MCRs) across Molina’s businesses in the third quarter were in line with JPMorgan’s expectations. Medical costs remained high but were stabilizing. Medicaid MCR nevertheless rose 0.3 percentage points from the previous quarter to 93%; the share of premiums spent on medical care continued to rise, squeezing margins.
The company maintained its 2026 guidance for premium revenue of 42 billion dollars and a consolidated MCR of 92.6%, but raised its expectations for both rate increases and medical cost growth by 0.5 percentage points, to 4.5% and 5.5%, respectively. Higher costs offset the additional rate increases, supporting the view that margins may be bottoming, rather than having already recovered.

Management expects premium revenue of at least 45 billion dollars in 2027. There is already some visibility on rates: the renewal cohort at the start of the year accounts for 55% of full-year premium revenue, and draft rates for 80% of that cohort show an average increase of roughly 7%. Together with the carryover effect of rate increases at the end of 2026, the known information covers roughly 70% of full-year premium revenue and points to a full-year rate increase of roughly 6%.
But medical cost growth is expected to reach 5.5%–6%, including a prudential margin of 0.5 percentage points, potentially offsetting most of the rate increase. The company expects the MCR for its existing Medicaid business to be at least flat year over year; additional profit improvement is possible only if cost growth is lower than expected.

The company’s fourth-quarter guidance assumes that the Florida FL CMS contract will contribute 1.5 billion dollars in revenue, but with an MCR as high as 99% and a pretax loss margin of 5%. The additional revenue expands scale while also weighing on profitability.
JPMorgan estimates that the contract needs to improve by at least 5 percentage points to break even: roughly 2 percentage points from the fading of the one-time reserve burden associated with new business, and the remaining roughly 3 percentage points mainly from a lower MCR, with some contribution from an improved administrative expense ratio. The complexity of patients’ conditions means improvement may take several quarters.

Starting in 2027, work requirements and eligibility reviews every six months will begin to affect Molina and its peers. Management expects cumulative membership losses of 9%–10% over the next several years and a 6% decline in comparable membership in 2027. Exiting MAPD and reducing Marketplace coverage will also create revenue headwinds.
But the pace of losses may be slower. States tend to retain enrollees through exemptions and simplified reviews, and some disenrollments may be deferred until 2028. In Nebraska, which implemented the measures earlier, 90% of those up for renewal successfully renewed. Management expects membership losses to be gradual and the impact on patient acuity mix to be limited; JPMorgan remains cautious about subsequent pressure.

As of the end of September, parent-company cash stood at 608 million dollars, close to the year-end target of 600 million dollars. Debt as a proportion of capital was 45%, also close to the year-end target of 44%. But total leverage in the model rose from 42.8 times in the second quarter to 69.8 times, and credit metrics remain under pressure from weak earnings.
JPMorgan maintains its underweight recommendation on Molina bonds: their spread is less than 30 basis points wider than Centene’s, yet roughly 70 basis points narrower than the BB-rated index, offering limited valuation compensation. A lower MCR, faster or more favorable state rate adjustments, and fewer disenrollments than expected could all improve the bank’s assessment.